A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy

NCT04352413 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

45

Enrollment

INDUSTRY

Sponsor class

Stopped The sponsor has adjusted its R\&D strategy.

Conditions

Small Cell Lung Cancer

Interventions

DRUG: PLM60

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.